Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

This article discusses a case of delayed onset perforating folliculitis linked to the use of sorafenib, but it reports no new clinical results.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study highlights that biological therapy, which stimulates the immune system through various methods like cytokine injections and immune checkpoint inhibition, shows promise for treating melanoma based on laboratory and clinical studies.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

This review reports that ritlecitinib, baricitinib, and deuruxolitinib, all JAK inhibitors, are effective treatments for moderate-to-severe alopecia areata, with differences in selectivity and onset of action, and suggests that emerging biologic therapies may enhance treatment by offering more targeted immune modulation.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

In this prospective study, dabrafenib and trametinib were associated with various skin side effects, including papillomas, hyperkeratosis, and acneiform eruptions in patients with metastatic melanoma.

Bempikibart may help regrow hair in people with alopecia areata.

This report describes a case where treatment with the JAK inhibitor ruxolitinib significantly improved beard growth in a patient with severe alopecia areata, emphasizing its potential benefits for populations where beard hair holds cultural significance.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

In this study, researchers found that the compound BMS-470539 induced a senescence-like state in fibroblasts from systemic sclerosis patients, reducing fibrosis-associated markers in vitro and decreasing skin thickness in a mouse model of skin fibrosis, suggesting a novel therapeutic strategy for managing fibroblast-driven diseases.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

In this study, sirolimus treatment reduced the size of venous malformations and improved anemia, transfusion dependence, and quality of life in patients with blue rubber bleb nevus syndrome, though mild adverse effects were reported.

This study presents the first documented case of dramatic hair regrowth in a systemic lupus erythematosus patient with refractory alopecia following tofacitinib therapy, suggesting a potential new application for JAK inhibitors in difficult-to-treat cutaneous SLE manifestations.

In this study, 96% of children with CNS tumors receiving MAPK and mTOR inhibitors experienced common, treatable skin reactions, occasionally requiring therapy adjustments.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.